BLU-945 suppresses ABCB1-mediated drug efflux and restores chemosensitivity in multidrug-resistant cancer cells
Related Experiment Video
Updated: Aug 13, 2026
Chung-Pu Wu1, Yen-Ching Li2, Ting-Yu Chen2
1Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan; Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan; Molecular Medicine Research Center, College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan; Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital, Taipei, 10507, Taiwan.
Abstract:
Chemotherapy remains a cornerstone of cancer treatment, yet its clinical efficacy is often limited by multidrug resistance (MDR). A major contributor to this phenomenon is the ATP-binding cassette transporter ABCB1 (P-glycoprotein; P-gp), which actively exports many chemotherapeutic agents from cancer cells, reducing intracellular drug accumulation and therapeutic effectiveness. Despite decades of effort, clinically effective ABCB1 inhibitors capable of overcoming this resistance mechanism have not been successfully developed. In this study, we examined whether BLU-945, a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target resistant EGFR mutations, could also modulate ABCB1 activity. Our findings demonstrate that BLU-945 stimulates ABCB1 ATPase activity, indicating direct interaction with the transporter consistent with substrate or modulator behavior. Notably, ABCB1-overexpressing cancer cells did not exhibit resistance to BLU-945, suggesting that elevated ABCB1 expression does not compromise its intrinsic anticancer activity. More importantly, BLU-945 significantly restored the sensitivity of ABCB1-overexpressing cancer cells to multiple cytotoxic agents in a concentration-dependent manner at sub-cytotoxic concentrations. Mechanistic studies further revealed that this chemosensitizing effect results from inhibition of ABCB1-mediated drug efflux rather than alterations in ABCB1 protein expression, leading to increased intracellular drug accumulation and enhanced cytotoxicity. Together, these findings reveal a previously unrecognized property of BLU-945 as a functional inhibitor of ABCB1-mediated drug transport. In addition to its activity as a mutant-selective EGFR inhibitor, BLU-945 may therefore serve as a dual-function agent capable of targeting oncogenic signaling while mitigating transporter-mediated chemoresistance, supporting its potential reprofiling in combination chemotherapy for ABCB1-overexpressing tumors.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
ABC Transporters: Exporter
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
